SAR: Safety ¹

Ryaltris was well tolerated with similar incidences of AEs compared with placebo or individual monotherapies.

GSP301 is a combination of olopatadine hydrochloride and mometasone furoate.     AE, adverse event; BID, twice daily; SAE, serious adverse event; SAR, seasonal allergic rhinitis; TEAE, treatment-emergent adverse event.      1. Hampel FC, et al. Allergy Asthma Proc. 2019;40:261-272; data on file.

PAR Study: Safety Results ¹

At week 52, the incidence of adverse events was comparable across treatments. Most adverse events were mild to moderate in severity

a1 pneumonia; 1 cellulitis; 1 cholelithiasis; 1 renal cell carcinoma; 1 anaplastic astrocytoma; 1 invasive ductal breast carcinoma. b1 appendicitis; 1 ectopic pregnancy. c1 nephrolithiasis; 1 cholelithiasis.     GSP301 is a combination of olopatadine hydrochloride and mometasone furoate.      PAR, perennial allergic rhinitis; SAE, serious adverse event; TEAE, treatment-emergent adverse event.     1. Segall, et al. Allergy Asthma Proc. 2019;40:301-310; data on file.